Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults
In its latest guidelines, dated August 8, 2022, the US National Institutes of Health (NIH) gave one of its strongest recommendations to Paxlovid for patients at high risk of progressing to severe COVID-19, regardless of vaccination status. The list of underlying medical Conditions that increase the risk of severe COVID-19 are longstanding, accounting for more … Read more
